Published in Oncology Business Week, April 4th, 2010
"For comparisons of antitumor activity between tumor lines, the LCK values are converted to an arbitrary rating; for example, the treatment effect is considered significant if the LCK >0.7 (Corbett et al., 2003). The drawback of using such a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.